Earnings call transcript: Loblaw Q1 2026 beats EPS, misses revenue

Loblaw delivered a mixed Q1 2026: EPS of 0.52 beat expectations of 0.5173, while revenue of 14.48B missed the 14.6B forecast. Adjusted EBITDA rose 6% to 1.7B CAD, online sales grew 20.3%, and the company raised its dividend 10% for a 15th straight annual increase. Management flagged ongoing inflation and pricing pressure, but reiterated confidence in 2026 guidance and noted roughly 1% EPS drag from East Gwillimbury and T&T U.S. investments.

Analysis

The key incremental signal is not the headline retail beat, but the mix shift toward higher-frequency, lower-ticket defensive consumption. That typically supports traffic and loyalty economics in the near term, but it also compresses the upside from broad-based inflation because customers are actively arbitraging price points and private label. In other words, Loblaw is winning share by becoming the “utility” basket, but that makes earnings more dependent on execution, mix, and operating leverage than on nominal price inflation.

The more important second-order effect is that management is effectively trading current margin for future density. Faster build costs and lower entry thresholds expand the set of viable markets, which is a structural advantage versus regional grocers with weaker balance sheets. The flip side is that the next 2-4 quarters likely show the most visible earnings drag from distribution center ramp and healthcare mix; that should cap multiple expansion even if sales remain resilient. The market is probably underestimating how much of this is a multi-year capacity build rather than a one-quarter retail story.

On the healthcare side, generic GLP-1 availability is a double-edged catalyst: it may pressure top-line pharmacy run-rate, but it also broadens patient adoption and should reinforce prescription traffic, attachment, and refill frequency over time. If drug pricing falls as expected, the near-term same-store sales optics may soften while the customer acquisition and loyalty effects improve. That means the right way to think about this is not EPS haircut today, but a potentially better long-duration pharmacy ecosystem with a temporary mix headwind.

For Nvidia, the article’s relevance is negative only at the margin: AI enthusiasm is increasingly being paired with real-world cost discipline and workflow automation at large retailers, which supports the broader AI capex narrative but not necessarily near-term chip beta. The better trade here is not chasing the AI complex on this headline; it is owning the consumer-utility compounder that is actually monetizing AI in operations before the market fully credits it.

Key Decisions for Investors

• Long L.TO / short XFN or a Canadian consumer staple basket for 4-8 weeks: Loblaw should outperform slower-moving staples if inflation remains sticky and defensive trade-down persists, but the pair limits downside if grocery CPI decelerates.
• Buy L.TO on pullbacks only; use a 1-3 month horizon and require a mid-single-digit drawdown to improve entry. Risk/reward is better on weakness because near-term execution is good but valuation should stay capped until DC and T&T U.S. drags fade.
• Sell out-of-the-money covered calls on L.TO against existing longs over the next 1-2 quarters. The thesis is range-bound upside with strong support from capital returns, but limited multiple expansion while capex/ramp costs persist.
• Avoid chasing NVDA off this print; if anything, fade near-term AI supply-chain momentum into strength. The retail AI adoption theme is supportive for long-duration spend, but it does not change chip demand enough to justify a new entry here on this catalyst.
• Consider a paired long EQB.TO / neutral L.TO exposure if you want to express the PC Financial transaction angle with less retail multiple risk. The cash release and buyback capacity are tangible, but the cleaner upside may sit with the counterparty rather than the retailer.